Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- KURA
- Price
- 9.09
- Stock movement up
- +0.37 (4.24%)
- Company name
- Kura Oncology Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 790.99M
- Ent value
- 1.10B
- Price/Sales
- 7.60
- Price/Book
- 3.26
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 6.05%
- 1 year return (CAGR)
- 23.00%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-01-22
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
KURA does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | 9.01 |
| Price to FCF | 9.52 |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 7.60 |
| Price to Book | 3.26 |
| EV to Sales | 10.60 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 87.02M |
| EPS (TTM) | -2.47 |
| FCF per share (TTM) | 0.95 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 104.03M |
| Gross profit (TTM) | 100.82M |
| Operating income (TTM) | -239.82M |
| Net income (TTM) | -216.88M |
| EPS (TTM) | -2.47 |
| EPS (1y forward) | -2.27 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 96.91% |
| Operating margin (TTM) | -230.53% |
| Profit margin (TTM) | -208.48% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 95.29M |
| Net receivables | 39.24M |
| Total current assets | 620.66M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 18.80M |
| Total assets | 649.38M |
| Accounts payable | 4.67M |
| Short/Current long term debt | 19.47M |
| Total current liabilities | 121.30M |
| Total liabilities | 406.84M |
| Shareholder's equity | 242.54M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | 87.80M |
| Capital expenditures (TTM) | 4.69M |
| Free cash flow (TTM) | 83.11M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -89.42% |
| Return on Assets | -33.40% |
| Return on Invested Capital | -85.51% |
| Cash Return on Invested Capital | 32.77% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 8.75 |
| Daily high | 9.14 |
| Daily low | 8.66 |
| Daily Volume | 1.17M |
| All-time high | 41.62 |
| 1y analyst estimate | 33.00 |
| Beta | 0.21 |
| EPS (TTM) | -2.47 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 3 Mar 2026 |
Downside potential
Loading...
Downside potential data
| KURA | S&P500 | |
| Current price drop from All-time high | -78.16% | -0.89% |
| Highest price drop | -86.69% | -19.00% |
| Date of highest drop | 11 Aug 2025 | 8 Apr 2025 |
| Avg drop from high | -78.24% | -2.49% |
| Avg time to new high | - | 6 days |
| Max time to new high | 322 days | 89 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
790.99M
Marketcap category
Small-cap
Description
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its lead product candidate includes ziftomenib, a selective investigational inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a selective investigational FTI for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies; and a clinical collaboration with Mirati Therapeutics, Inc. to evaluate the combination of KO-2806 and adagrasib, a KRASG12C inhibitor in patients with NSCLC. The company is headquartered in San Diego, California.
Employees
192
Website
Investor relations
-
SEC filings
CEO
Troy E. Wilson
Country
USA
City
San Diego
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page